Regeneron Pharmaceuticals (REGN) Gross Profit (2009 - 2026)

Regeneron Pharmaceuticals has reported Gross Profit for 18 years, with the latest figure at $3.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 16.94% year-over-year to $3.3 billion; the trailing twelve-month figure through Mar 2026 stood at $14.0 billion (up 6.84% YoY), and the FY2025 full-year result was $13.4 billion, up 2.05% from the prior year.
• Gross Profit for Q1 2026 stood at $3.3 billion, down from $3.7 billion in the prior quarter.
• The five-year high for Gross Profit was $3.7 billion in Q4 2025, with the low at -$157.3 million in Q1 2022.
• Average Gross Profit over 5 years is $2.8 billion, with a median of $3.2 billion recorded in 2023.
• Year-over-year, Gross Profit tumbled 106.71% in 2022 and surged 2429.55% in 2023.
• Tracing REGN's Gross Profit over 5 years: stood at -$138.4 million in 2022, then surged by 2429.55% to $3.2 billion in 2023, then grew by 7.39% to $3.5 billion in 2024, then gained by 8.21% to $3.7 billion in 2025, then dropped by 11.67% to $3.3 billion in 2026.
• The last three Gross Profit figures came in at $3.3 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.5 billion (Q3 2025), per Business Quant data.

Peer Comparison